RT Journal Article
T1 Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF V600E mutation
A1 García Silva, Susana
A1 Benito Martín, Alberto
A1 Sánchez Redondo, Sara
A1 Hernández Barranco, Alberto
A1 Ximénez Embún, Pilar
A1 Nogues Vera, Laura
A1 Mazariegos, Marina S.
A1 Brinkmann, Kay
A1 Amor López, Ana
A1 Meyer, Lisa
A1 Rodríguez, Carlos
A1 García Martín, Carmen
A1 Boskovic, Jasminka
A1 Letón, Rocío
A1 Montero, Cristina
A1 Robledo, Mercedes
A1 Santambrogio, Laura
A1 Sue Brady, Mary
A1 Szumera Ciećkiewicz, Anna
A1 Kalinowska, Iwona
A1 Skog, Johan
A1 Noerholm, Mikkel
A1 Muñoz, Javier
A1 Ortiz Romero, Pablo Luis
A1 Ruano, Yolanda
A1 Rodríguez Peralto, José Luis
A1 Rutkowski, Piotr
A1 Peinado, Héctor
AB Liquid biopsies from cancer patients have the potential to improve diagnosis and prognosis. The assessment of surrogatemarkers of tumor progression in circulating extracellular vesicles could be a powerful non-invasive approach in this setting.Wehave characterized extracellular vesicles purified from the lymphatic drainage also known as exudative seroma (ES) of stageIII melanoma patients obtained after lymphadenectomy. Proteomic analysis showed that seroma-derived exosomes areenriched in proteins resembling melanoma progression. In addition, we found that the BRAFV600E mutation can be detected inES-derived extracellular vesicles and its detection correlated with patients at risk of relapse.
PB Rockefeller University Press
SN 0022-1007
SN 1540-9538
YR 2019
FD 2019-04-11
LK https://hdl.handle.net/20.500.14352/131088
UL https://hdl.handle.net/20.500.14352/131088
LA eng
NO García-Silva S, Benito-Martín A, Sánchez-Redondo S, Hernández-Barranco A, Ximénez-Embún P, Nogués L, et al. Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF V600E mutation. Journal of Experimental Medicine 2019;216:1061–70. https://doi.org/10.1084/jem.20181522.
DS Docta Complutense
RD 23 mar 2026